GO
Loading...

Pharmaceuticals

More

  • Amgen And Genentech: A Big Biotech Double Play Monday, 10 Mar 2008 | 10:50 AM ET
    AMGEN

    This is a big week for the world's top-two biotechnology companies and their investors. Amgen goes before an FDA Advisory Committee Thursday about the side effects of its bread-and-butter franchise Aranesp.

  • First, Pfizer gave up on its inhaled insulin Exubera, then NovoNordisk threw in the towel and now it looks like Lilly is going to bow out. Alkermes, which is working on a palm-sized product called, "AIR Insulin," put out a press release today saying it expects its partner on the device, Lilly, to decide next week that it will exit the deal. ALKS shares hit a new low on the news.

  • Analyst: Pfizer Should Buy Amgen or Wyeth Friday, 7 Mar 2008 | 10:48 AM ET

    I thought I was finished with the post-Pfizer analyst meeting reaction with yesterday's post, but when an extraordinarily bearish 77-page research note from Credit Suisse big pharma analyst Catherine Arnold arrived in my inbox this morning, I had to do one more installment. She thinks Pfizer should buy Wyeth or Amgen...

  • Walk The Line Thursday, 6 Mar 2008 | 6:30 PM ET

    Traders are glued to the charts as the S&P 500 tests the crucial January low. Is it time to start buying?

  • Pfizer Analyst Day: The Analysts React Thursday, 6 Mar 2008 | 10:16 AM ET

    Pfizer held its analyst day yesterday and the stock closed at a new multi-year low. This morning the shares are under a little bit of pressure again as analyst reaction to the event pours in.

  • FDA Turns Over Dendreon Documents Wednesday, 5 Mar 2008 | 3:49 PM ET

    When I got back from the Pfizer analyst meeting in New York City this afternoon, I found a treasure trove of PDF documents in one of my inboxes from a couple of Dendreon/Provenge proponents from their Freedom of Information Act request to the Food and Drug Administration...

  • Pfizer CEO: We're Ready For Generic Lipitor Wednesday, 5 Mar 2008 | 2:25 PM ET

    I'm in the press room at the midtown Manhattan hotel where Pfizer is holding its analyst meeting. There's just over half a dozen reporters here and we're nearly outnumbered by PR folks. As one of them remarked, the press turnout for an event like this just isn't what it used to be...

  • Pfizer Turns to Emerging Markets for Growth Wednesday, 5 Mar 2008 | 8:36 AM ET

    Pfizer, which is struggling to remain competitive amid generic competition for many of its products, Wednesday said it hopes to expand its sales in Asia and other emerging markets.

  • Baxter, Biogen Idec & Elan Subjects of Broken Embargoes Wednesday, 5 Mar 2008 | 8:15 AM ET

    Embargoes imposed by scientific groups and medical journals will once again be put to the test over the next couple of months.

  • Pfizer Not Getting The Love Before Analyst Meeting Tuesday, 4 Mar 2008 | 3:38 PM ET

    The day before Pfizer's analyst meeting tomorrow investors are not showing much love for the beaten-down Dow component. PFE's trading in the early going today at its lowest level since December 2005.

  • Glaxo Wins FDA Priority Review for Blood Drug Monday, 3 Mar 2008 | 11:04 AM ET

    GlaxoSmithKline's experimental platelet-boosting drug Promacta has been granted priority review by U.S. health regulators, boosting prospects for its early launch, Europe's biggest drugmaker said on Monday.

  • Drug Money Still A "Healthy Flow" To Democrats Monday, 3 Mar 2008 | 9:29 AM ET

    On the eve of the make-or-break Texas-Ohio primaries for Sen. Hillary Clinton, she remains in first place in at least one "poll." The Center for Responsive Politics has updated its list of top pharmaceuticals/health products-industry money recipients based on the most recent campaign finance reports and the former First Lady edges out Sen. Barack Obama...

  • Glaxo's Tykerb Goes Head-to-Head with Herceptin Friday, 29 Feb 2008 | 5:10 AM ET

    GlaxoSmithKline's new breast cancer drug Tykerb is to go head-to-head with Genentech's blockbuster Herceptin to see whether one is better or if patients should get both.

  • Lightning Round: Medco, Amgen, Yum! and More Thursday, 28 Feb 2008 | 8:12 PM ET

    Cramer makes the call on viewers' favorite stocks.

  • Bayer Misses Forecasts; CEO Upbeat on 2008 Thursday, 28 Feb 2008 | 1:12 PM ET

    German drugs and chemicals group Bayer missed fourth-quarter earnings expectations Thursday, sending shares 4.7 percent lower on the DAX, but CEO Werner Wenning told CNBC he remains optimistic about the company’s outlook for this year.

  • Lechleiter Likes Lilly--A Lot Thursday, 28 Feb 2008 | 9:50 AM ET

    When Schering-Plough Chairman and CEO Fred Hassan recently decided to buy another $2 million worth of SGP shares in the wake of the Vytorin study takedown, the company put out a press release.

  • Major European Companies Report Mixed Earnings Thursday, 28 Feb 2008 | 6:53 AM ET

    European earnings failed to drive broader European markets higher, as disappointing numbers from bigger names and cautious guidance mostly pushed shares in reporting companies lower.

  • Bayer Profit Misses Forecasts; Upbeat on 2008 Thursday, 28 Feb 2008 | 4:09 AM ET

    Bayer's quarterly profits missed market expectations, but the German drugs and chemicals group was upbeat about 2008 and said its healthcare and agrochemicals units would drive earnings.

  • Onyx Hires New CEO--But Here's What You Won't Find In PR Wednesday, 27 Feb 2008 | 3:28 PM ET

    Recently I've blogged and raised the question in an interview about whether Onyx Pharmaceuticals might be having a tough time finding a new leader. Well, nearly six months since longtime Chairman and CEO Hollings Renton announced his plans to retire this year, the biotech company has filled the spot.

  • Prana Biotechnology: Why I Wanted To Do Their Story Tuesday, 26 Feb 2008 | 1:13 PM ET

    I often get pitched by PR people who want me to do a story on their micro-cap biotech company. And I almost always turn them down. I know that most of the sector toils in the eight and nine digit market value space and that there's a bit of a Catch-22 at work.